Bristol Myers Squibb Posts Q3 Earnings Results

The pharmaceutical company reports $2.16 billion in third-quarter net income.

Updated on Oct. 29, 2026 in Public Companies

Isometric editorial illustration of a single glass laboratory beaker on a neutral surface, symbolizing pharmaceutical financial performance. — Bristol Myers Squibb reported $13.07 billion in third-quarter revenue, with earnings of $1.05 per share for the 2026 period. AI Illustration. Upload story photo >

Live Poll

Is the current growth in pharmaceutical stocks a reliable indicator of broader market health?

Bristol Myers Squibb reported third-quarter revenue of $13.07 billion for the 2026 reporting period. The company recorded net income of $1.05 per share alongside adjusted earnings of $1.35 per share.

Why it matters

These results provide insight into the financial performance of the Princeton-based company as it navigates the 2026 fiscal landscape. The company also issued updated expectations for its full-year earnings and revenue performance.

Bristol Myers Squibb reported Q3 net income of $2.16 billion with net income at $1.05 per share. Full-year earnings are projected between $6.35 and $6.55 per share.

The players

Bristol Myers Squibb

This global biopharmaceutical company is based in Princeton, N.J., and focuses on developing medicines for serious diseases.

The details

Bristol Myers Squibb, headquartered in Princeton, N.J., saw its shares rise 12% since the start of 2026. This performance trails slightly behind the S&P 500 index, which has grown 13% during the same timeframe.

Q3 2026 served as the primary reporting period for these earnings and revenue figures.

Market Landscape

Bristol Myers Squibb stock has seen a 41% increase over the last 12 months, reflecting a broader trend in pharmaceutical valuation. Its year-to-date performance remains closely aligned with the 13% gain recorded by the S&P 500 index.

Investors can track the company's full-year outlook, which targets revenue between $49.75 billion and $50.25 billion. These figures help stakeholders gauge the firm's stability as it continues its annual operations.

The takeaway

Maintaining a steady outlook for the remainder of the year suggests the company is focused on meeting its established financial guidance. Shareholders should monitor how the firm manages its earnings targets relative to its projected revenue range.